Literature DB >> 1675146

Modulation of the hypothermic and hyperglycaemic effects of 8-OH-DPAT by alpha 2-adrenoceptor antagonists.

M J Durcan1, K M Wozniak, M Linnoila.   

Abstract

1. The effects of pretreatment with two novel and relatively specific alpha 2-adrenoceptor antagonists on the hypothermic and hyperglycaemic responses induced by the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) were investigated in mice. The alpha 2-adrenoceptor antagonists used were, atipamezole, which occupies both central and peripheral receptors, and L 659,066, which poorly penetrates the blood brain barrier. 2. Atipamezole (1 and 3 mg kg-1) alone had no effect on body temperature but significantly attenuated the 8-OH-DPAT-induced hypothermic response. The hyperglycaemic effect of 8-OH-DPAT was also attenuated by pretreatment with atipamezole; however, 3 mg kg-1 atipamezole did cause some hypoglycaemia when administered alone. 3. Pretreatment with L 659,066 (3-30 mg kg-1) failed to alter the hypothermic effects of 8-OH-DPAT. All doses of L 659,066 tested attenuated 8-OH-DPAT-induced hyperglycaemia, but the highest dose (30 mg kg-1) produced hypoglycaemia when administered alone. 4. The results suggest that the attenuation of 8-OH-DPAT-induced hypothermia by alpha 2-adrenoceptor antagonist may be centrally mediated whereas the blockade of 8-OH-DPAT-induced hyperglycaemia may involve peripheral mechanisms.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1675146      PMCID: PMC1917902          DOI: 10.1111/j.1476-5381.1991.tb12157.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

1.  Evidence that 8-hydroxy-2-(n-dipropylamino)tetralin (8-OH-DPAT) is a selective alpha 2-adrenoceptor antagonist on guinea-pig submucous neurones.

Authors:  J Crist; A Surprenant
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

2.  Marked increases in plasma catecholamine concentrations precede hypotension and bradycardia caused by 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in conscious rats.

Authors:  G Bagdy; K Szemeredi; D L Murphy
Journal:  J Pharm Pharmacol       Date:  1989-04       Impact factor: 3.765

3.  Involvement of a central nervous pathway in yohimbine-induced insulin secretion.

Authors:  G Ribes; D Hillaire-Buys; R Gross; J P Blayac; M M Loubatières-Mariani
Journal:  Eur J Pharmacol       Date:  1989-03-21       Impact factor: 4.432

4.  Frequency-dependence of serotonin autoreceptor but not alpha 2-adrenoceptor inhibition of [3H]-serotonin release in rat hypothalamic slices.

Authors:  P Blier; R Ramdine; A M Galzin; S Z Langer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989 Jan-Feb       Impact factor: 3.000

5.  Yohimbine increases plasma insulin concentrations of dogs.

Authors:  W H Hsu; D D Schaffer; M H Pineda
Journal:  Proc Soc Exp Biol Med       Date:  1987-03

6.  Activation of thermogenesis of brown fat in rats by baclofen.

Authors:  J I Addae; N J Rothwell; M J Stock; T W Stone
Journal:  Neuropharmacology       Date:  1986-06       Impact factor: 5.250

7.  Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors.

Authors:  G A Gudelsky; J I Koenig; H Y Meltzer
Journal:  Neuropharmacology       Date:  1986-12       Impact factor: 5.250

8.  Generalization of the discriminative stimulus properties of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and ipsapirone to yohimbine.

Authors:  J C Winter
Journal:  Pharmacol Biochem Behav       Date:  1988-01       Impact factor: 3.533

9.  A peripherally acting alpha-2 adrenoceptor antagonist: L-659,066.

Authors:  B V Clineschmidt; D J Pettibone; V J Lotti; H B Hucker; B M Sweeney; D R Reiss; E V Lis; J R Huff; J Vacca
Journal:  J Pharmacol Exp Ther       Date:  1988-04       Impact factor: 4.030

10.  Cardiovascular response to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in the rat: site of action and pharmacological analysis.

Authors:  J R Fozard; A K Mir; D N Middlemiss
Journal:  J Cardiovasc Pharmacol       Date:  1987-03       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.